We narrowed to 15,597 results for: jun

#75033-AAV1

Ready-to-use AAV1 particles produced from pAAV CD68-hM4D(Gi)-mCherry (#75033). In addition to the viral particles, you will also receive purified pAAV CD68-hM4D(Gi)-mCherry plasmid DNA. CD68-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced microglial inhibition. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Grace et al Proc Natl Acad Sci U S A. 2016 Jun 14;11

March 27, 2019

Academic Institutions and Nonprofits only

#137122-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-Con/Fon-GCaMP6F (#137122). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Fon-GCaMP6F plasmid DNA. EF1a-driven, Cre and Flp-dependent expression of GCaMP6f. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

July 17, 2020

Academic Institutions and Nonprofits only

#137141-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Coff/Fon-ChR2(ET/TC)-EYFP (#137141). In addition to the viral particles, you will also receive purified pAAV-nEF-Coff/Fon-ChR2(ET/TC)-EYFP plasmid DNA. nEF-driven, Flp-dependent expression of ChR2(E123T/T159C)-EYFP (inhibited in presence of Cre) for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 6, 2021

Academic Institutions and Nonprofits only

#200013

Knockout library containing ~10,000 sgRNAs targeting 1,980 human druggable genes (5 sgRNAs per gene and 100 non-targeting control sgRNAs).

Lianxin Liu

Zheng et al Adv Sci (Weinh). 2023 Aug;10(22):e220679

May 9, 2023

Academic Institutions and Nonprofits only

#158757-AAV8

Ready-to-use AAV8 particles produced from pAAV-CAG-SomaGCaMP6f2 (#158757). In addition to the viral particles, you will also receive purified pAAV-CAG-SomaGCaMP6f2 plasmid DNA. CAG-driven expression of soma-targeting GCaMP6f2. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Shemesh et al Neuron. 2020 Jun 26. pii: S0896-6273(20)

Feb. 23, 2021

Academic Institutions and Nonprofits only

#137142-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Fon-ChR2-mCherry (#137142). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Fon-ChR2-mCherry plasmid DNA. nEF-driven, Cre and Flp-dependent expression of channelrhodopsin fused to mCherry for optogenetic activation.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Feb. 25, 2021

Academic Institutions and Nonprofits only

#137144-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Coff/Fon-ChR2-mCherry (#137144). In addition to the viral particles, you will also receive purified pAAV-nEF-Coff/Fon-ChR2-mCherry plasmid DNA. nEF-driven, Flp-dependent expression of ChR2-mCherry for optogenetic activation (inhibited in presence of Cre). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

April 8, 2021

Academic Institutions and Nonprofits only

#137122-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Fon-GCaMP6F (#137122). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Fon-GCaMP6F plasmid DNA. EF1a-driven, Cre and Flp-dependent expression of GCaMP6f. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

March 12, 2021

Academic Institutions and Nonprofits only

#111068-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn-dLight1.2 (#111068). In addition to the viral particles, you will also receive purified pAAV-hSyn-dLight1.2 plasmid DNA. Synapsin-driven expression of dLight1.2 dopamine sensor. This sensor has a slightly increased dynamic range and is better for 2P imaging in vivo. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Patriarchi et al Science. 2018 Jun 29;360(6396). pii: sci

Feb. 25, 2021

Academic Institutions and Nonprofits only

#137154-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Coff/Fon-NpHR3.3-EYFP (#137154). In addition to the viral particles, you will also receive purified pAAV-nEF-Coff/Fon-NpHR3.3-EYFP plasmid DNA. nEF-driven, Flp-dependent expression of NpHR3.3-EYFP (inhibited in presence of Cre) for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

April 8, 2021

Academic Institutions and Nonprofits only

#137127-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-sRGECO (#137127). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-sRGECO plasmid DNA. EF1a-driven, Cre-dependent expression of cytosolic sRGECO calcium sensor (inhibited in presence of Flp). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 18, 2021

Academic Institutions and Nonprofits only